Roche reports positive data from Phase III influenza treatment trial

Roche has announced positive topline data from the Phase III CENTERSTONE clinical trial of Xofluza (baloxavir marboxil), an antiviral treatment for influenza infection.

A single-dose oral treatment, Xofluza is designed to hinder viral replication by stopping the cap-dependent endonuclease protein, to lower the infectiousness and disease duration.